カプセル内視鏡市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed gastroenterology journals, clinical publications, and authoritative medical device and health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), European Medicines Agency (EMA) Medical Device Regulation (MDR), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE), European Society of Gastrointestinal Endoscopy (ESGE), World Gastroenterology Organisation (WGO), World Endoscopy Organization (WEO), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule, Centers for Disease Control and Prevention (CDC) Division of Digestive Diseases, National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI/PubMed), World Health Organization (WHO) Global Health Observatory, Healthcare Cost and Utilization Project (HCUP), National Health Service (NHS) UK Digital, Japan Gastroenterological Endoscopy Society (JGES), ECRI Institute Health Devices Database, and national medical device registries from key markets. These sources were utilized to collect procedure volume statistics, 510(k) clearance and PMA approval data, clinical safety and efficacy studies for small bowel capsule endoscopy versus colon capsule endoscopy versus esophageal capsule endoscopy, reimbursement codes and rates, prevalence data for obscure gastrointestinal bleeding (OGIB) and Crohn's disease, and competitive landscape analysis for capsule endoscopes and workstation systems.

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of R&D, heads of regulatory affairs, directors of quality assurance, and directors of commercial operations from companies that manufacture endoscopic devices, OEM contract manufacturers for capsules, and suppliers of image sensor technologies were examples of supply-side sources. Board-certified gastroenterologists, colorectal surgeons, directors of GI fellowships, medical directors of hospital endoscopy units, clinical coordinators of ambulatory surgery centers (ASCs), procurement leads from integrated delivery networks (IDNs), and members of health technology assessment (HTA) committees were among the demand-side sources. Primary research confirmed next-generation capsule pipeline timelines (including AI-integrated retrieval and extended battery life technologies), validated market segmentation across product types (capsule endoscopes versus systems), and collected data on reimbursement dynamics for hospital inpatient versus ASC outpatient settings, pricing strategies for disposable capsules versus reusable workstations, and clinical adoption patterns for OGIB diagnosis versus Crohn's monitoring.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (28%), Director Level (32%), Others (40%)

• By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping and procedure volume analysis specific to wireless capsule endoscopy. The methodology included:

• Identification of 35+ key manufacturers and assemblers across North America, Europe, Asia-Pacific, and Latin America specializing in capsule endoscopy devices and companion systems

• Product mapping across small bowel capsule endoscopes, esophageal capsule endoscopes, colon capsule endoscopes, and workstation/data recorder systems

• Analysis of reported and modeled annual revenues specific to capsule endoscopy product portfolios, excluding traditional endoscopy and enteroscopy device revenues

• Coverage of manufacturers representing 70-75% of global market share in 2024, including specialized pure-play capsule companies and diversified endoscopy conglomerates

• Extrapolation using bottom-up (procedure volume × average selling price by country, differentiated by indication: OGIB, Crohn's disease surveillance, and small intestine tumor screening) and top-down (manufacturer revenue validation, adjusted for regional distribution channels and service contract revenues) approaches to derive segment-specific valuations for capsule endoscopes versus systems and hospital end-users versus ambulatory surgery centers